Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Period	PE Ratio
2020-12-31	77.13
2021-12-31	61.70
2022-12-31	84.14
2023-12-31	84.14
2024-12-31	57.84
2025-12-31	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HLN	$9.26	-0.38%	7.90M
3
4
5

Haleon plc American Depositary Shares (Each representing two) (HLN) PE Ratio

PE Ratio Data

Get Haleon plc American Depositary Shares (Each representing two) Data in Excel

More HLN Financial Data